Table 4.
Multivariable Models for Symptom Outcomes
Outcome | Number of symptomsa R2 = .30 |
Symptom severity indexb R2 = .38 |
Depressive symptomsc R2 = .47 |
Anxietyd R2 = .32 |
||||
---|---|---|---|---|---|---|---|---|
Predictor | Coefficient (SE) | p | Coefficient (SE) | p | Coefficient (SE) | p | Coefficient (SE) | p |
Age | −0.06 (0.02) | <. 01 | −0.32 (0.10) | <.01 | −0.11 (0.04) | .01 | −0.08 (0.04) | .04 |
Number of comorbid conditions | 0.56 (0.07) | < .01 | 3.68 (0.45) | <.01 | 0.83 (0.20) | <.01 | 0.23 (0.20) | .25 |
Social isolation | 0.11 (0.02) | < .01 | 0.79 (0.12) | <.01 | 0.72 (0.05) | <.01 | 0.55 (0.05) | <.01 |
Race/Ethnicity | ||||||||
Hispanic | 0.17 (0.43) | .69 | 5.41 (2.70) | .04 | 1.53 (1.17) | .19 | 0.23 (1.20) | .85 |
Non-Hispanic other races | 0.77 (0.60) | .20 | 9.46 (3.79) | <.01 | 0.00 (1.63) | .99 | −0.73 (1.66) | .67 |
Non-Hispanic White | Ref. | Ref. | Ref. | Ref. | ||||
Income meets needs | ||||||||
Meets | −0.31 (0.64) | .63 | −11.52 (4.04) | < .01 | −2.91 (1.76) | .10 | 0.17 (1.80) | .92 |
Barely | −0.09 (0.64) | .88 | −6.25 (3.77) | < .01 | −1.38 (1.64) | .40 | 1.43 (1.69) | .40 |
Not all | Ref. | - | Ref. | - | Ref. | - | Ref. | - |
Level of education | ||||||||
More than high school | −0.59 (0.40) | .14 | −2.23 (2.48) | .37 | −0.85 (1.08) | .43 | −0.25 (1.10) | .82 |
High school or less | Ref. | Ref. | Ref. | Ref. | ||||
Marital status | ||||||||
Not married | −0.25 (0.36) | .49 | 1.47 (2.28) | .52 | 0.87 (0.99) | .38 | −0.70 (1.01) | .49 |
Married | Ref. | Ref. | Ref. | Ref. | ||||
Population of residence | ||||||||
<100,000 people | −0.83 (0.39) | .04 | −3.79 (2.47) | .13 | −3.10 (1.07) | < .01 | −2.70 (1.11) | .02 |
100,000 or more | Ref. | Ref. | Ref. | Ref. | ||||
Cancer and treatment | ||||||||
Female breast chemotherapy/other targeted therapy | 5.81 (3.05) | .06 | 0.83 (1.32) | .53 | 0.11 (1.36) | .93 | ||
Female colorectal/GI | 0.27 (0.70) | .69 | 6.20 (4.38) | .16 | −0.46 (1.91) | .81 | −0.85 (1.96) | .66 |
Male colorectal/GI | 2.72 (0.80) | < .01 | 13.96 (5.06) | < .01 | 0.72 (2.20) | .74 | −0.89 (2.25) | .69 |
Female other | 0.45 (0.54) | .40 | 9.83 (3.36) | < .01 | 1.40 (1.46) | .34 | −0.81 (1.49) | .58 |
Male other | 1.22 (0.58) | .03 | 10.36 (3.61) | < .01 | 0.61 (1.56) | .70 | −2.02 (1.60) | .21 |
Female breast hormonal therapy | Ref. | Ref. | - | Ref. | Ref. | |||
Metastatic cancer | ||||||||
Yes | 0.45 (0.34) | .19 | 2.14 (2.15) | .32 | 1.34 (0.94) | .15 | 0.96 (0.49) | .63 |
No | Ref. | Ref. | Ref. | Ref. |
Note.
Number of symptoms-potential range 0–17, includes depression and anxiety, higher score = more symptoms;
Summed symptom severity-potential range 0–150, without depression and anxiety, higher score = greater severity;
Center for Epidemiological-Depression scale (CES-D)-potential range 0–60, higher score = worse depression;
Anxiety Patient Reported Outcomes Measurement Information System (PROMIS)-T scores range 43.2–83.1, higher score = more anxiety